Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features

PURPOSE:To predict programmed death-ligand 1 (PD-L1) expression of tumor cells in non-small cell lung cancer (NSCLC) patients by using a radiomics study based on CT images and clinicopathologic features. MATERIALS AND METHODS:A total of 390 confirmed NSCLC patients who performed chest CT scan and i mmunohistochemistry (IHC) examination of PD-L1 of lung tumors with clinic data were collected in this retrospective study, which were divided into two cohorts namely, training (n = 260) and validation (n = 130) cohort. Clinicopathologic features were compared between two cohorts. Lung tumors were segmented by using ITK-snap kit on CT images. Total 200 radiomic features in the segmented images were calculated using in-house texture analysis software, then filtered and minimized by least absolute shrinkage and selection operator (LASSO) regression to select optimal radiomic features based on its relevance of PD-L1 expression status in IHC results and develop radiomics signature. Radiomics signature and clinicopathologic risk factors were incorporated to develop prediction model by using multivariable logistic regression analysis. The receiver operating characteristic (ROC) curves were generated and the areas under the curves (AUC) were reckoned to predict PD-L1 expression in both training and validation cohorts. RESULTS:In 200 extracted radiomic features, 9 were selected to develop radiomics signature. In univariate analysis, PD-L1 expression of lung tumors was significantly correlated with radiomics signature, histologic type, and histologic grade (p < 0.05, respectively). However, PD-L1 expression was not correlated with gender, age, tumor location, CEA level, TNM stage, and smoking (p > 0.05). For prediction of PD-L1 expression, the prediction model that combines radiomics signature and clinicopathologic features resulted in AUCs of 0.829 and 0.848 in the training and validation cohort, respectively. CONCLUSION:The prediction model that incorporates the radiomics signature and clinical risk factors has potential to facilitate the individualized prediction of PD-L1 expression in NSCLC patients and identify patients who can benefit from anti-PD-L1 immunotherapy.